Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
Orchestra BioMed Holdings, Inc. - Ordinary Shares (OBIO)
Company Research
Source: GlobeNewswire
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for expanding use of AVIM-enabled devices to manage blood pressure and improve cardiovascular function for hypertensive patients with high cardiovascular risk,” commented David Hochman, Chairman, Chief Executive Officer and Founder of Orchestra BioMed. “As we age, our arteries naturally lose elasticit
Show less
Read more
Impact Snapshot
Event Time:
OBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OBIO alerts
High impacting Orchestra BioMed Holdings, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
OBIO
News
- Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock [Yahoo! Finance]Yahoo! Finance
- Orchestra BioMed (NASDAQ:OBIO) is now covered by analysts at TD Cowen. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- Orchestra BioMed (NASDAQ:OBIO) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.MarketBeat
- Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI MeetingGlobeNewswire
- Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements [Yahoo! Finance]Yahoo! Finance
OBIO
Sec Filings
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- 11/26/25 - Form 4
- OBIO's page on the SEC website